These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26615885)

  • 1. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
    Gargano EM; Perspicace E; Carotti A; Marchais-Oberwinkler S; Hartmann RW
    Bioorg Med Chem Lett; 2016 Jan; 26(1):21-4. PubMed ID: 26615885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.
    Marchais-Oberwinkler S; Xu K; Wetzel M; Perspicace E; Negri M; Meyer A; Odermatt A; Möller G; Adamski J; Hartmann RW
    J Med Chem; 2013 Jan; 56(1):167-81. PubMed ID: 23145773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
    Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
    Gargano EM; Perspicace E; Hanke N; Carotti A; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2014 Nov; 87():203-19. PubMed ID: 25259513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters.
    Perspicace E; Giorgio A; Carotti A; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2013 Nov; 69():201-15. PubMed ID: 24036043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
    Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Reed MJ; Potter BV
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):204-7. PubMed ID: 16337736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
    Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.
    Vuorinen A; Engeli R; Meyer A; Bachmann F; Griesser UJ; Schuster D; Odermatt A
    J Med Chem; 2014 Jul; 57(14):5995-6007. PubMed ID: 24960438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis.
    Vuorinen A; Engeli RT; Leugger S; Kreutz CR; Schuster D; Odermatt A; Matuszczak B
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2982-2985. PubMed ID: 28506753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
    Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
    Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
    Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
    Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog.
    Gargano EM; Allegretta G; Perspicace E; Carotti A; Van Koppen C; Frotscher M; Marchais-Oberwinkler S; Hartmann RW
    PLoS One; 2015; 10(7):e0134754. PubMed ID: 26230928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.
    Wetzel M; Marchais-Oberwinkler S; Hartmann RW
    Bioorg Med Chem; 2011 Jan; 19(2):807-15. PubMed ID: 21211981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
    Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
    Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.